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Summary
Clinically overt central nervous system (CNS)
involvement occurs in 10%-15% of patients with advanced
breast cancer.
Patients and methods: The International Breast Cancer
Study Group (IBCSG)conducted a dose-finding phase I trial
of epirubicin (E) and docetaxel (D) as first-line therapy in
advanced breast cancer patients. The study was expanded into
a phase II at the recommended doses of E 90 mg/m2 and D 75
mg/m2 every three weeks. From July 1996 to May 1998, a total
of 92 patients (median age 50 years) entered the two studies.
Results: Twenty-eight out of ninety-two patients treated
with the combination of E and D (30%) developed CNS
metastases (95% confidence limits, 26%-35%), which were cere-
bral in twenty-five patients, leptomeningeal in two, and both in
one. Of these 28 patients, 19 (68%) had an objective response.
Median time for the development of CNS metastases from the
start of chemotherapy was 15 months (range 5-42), if excluding
the 6 patients presenting CNS progression within 3 months
from start of treatment. It is notable that 11 patients (39%) had
progression in the CNS only. Median survival from appear-
ance of brain metastases in the whole group was only three
months (range 1-22). C-erbB-2 overexpression was found in 14
out of 16 patients (87%) in whom the assay was performed (3+
in 10, 2+ in 1 and 1+ in 3 cases).
Conclusions: As anthracycline- and taxane-containing regi-
mens are increasingly used both in the metastatic and in the
adjuvant setting, a careful monitoring of any neurological
symptom is advisable. Our preliminary observation on the
possible increase of incidence of CNS involvement in patients
with advanced breast cancer receiving this effective drug com-
bination requires further evaluation, j
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Introduction
Central nervous system (CNS) metastases from breast
cancer are becoming increasingly evident as patients live
longer, because of better adjuvant and palliative treat-
ments, and possibly because better diagnostic procedures
(CT scan, MRI) are now available. Although breast
cancer is the second most common cause of brain metas-
tases, clinically overt manifestations occur in approxi-
mately 10%-15% of patients only [1]. On the other hand,
an autopsy study in 1177 cases revealed a 23.6% incidence
[2] in the very terminal phase of the disease.
So far, no follow-up program includes routine brain
CT scan, unless symptoms are present, because of the
overall low incidence of this kind of metastatic spread
compared with other more common sites of relapse such
as bone, soft tissues, or viscera.
Although the role of chemotherapy in cerebral metas-
tases is still controversial, recent data indicate a similar
response rate of systemic disease and cerebral disease to
chemotherapy in patients with metastatic breast cancer
[3, 4], thus refuting the common belief that diagnostic
procedures should be undertaken only in case of a
suggestive clinical picture.
Anthracyclines and taxanes are the most active drugs
against breast cancer, achieving in combination an overall
response rate ranging from 52% to 76% [5-7] with
sustained activity at all disease sites. In 1996, the Inter-
national Breast Cancer Study Group (IBCSG) con-
ducted a dose-finding phase I trial of epirubicin (E) and
docetaxel (D) as first-line therapy in metastatic or lo-
cally advanced breast cancer (LABC) [8]. The study was
expanded, after the determination of the maximum
tolerated doses of the combination, into a phase II study
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using the recommended doses of E 90 mg/m2 and D 75 Table l. Patient characteristics.
mg/m2 every three weeks without granulocyte colony-
stimulating factor (G-CSF) support [9].
We report a high incidence of CNS relapse in the
whole group of patients treated with this drug combina-
tion, even in those achieving an initial response to the
treatment, with a significant incidence of CNS involve-
ment as unique site of disease progression.
Patients and methods
Ninety-two patients with metastatic or locally advanced breast cancer
were enrolled in two studies. The main eligibility criteria for the phase I
study have been published elsewhere [8] and included: histologically or
cytologically proven metastatic or locally advanced breast cancer, no
prior chemotherapy for metastatic disease, possible prior hormonal
therapy for advanced disease, adjuvant or neoadjuvant hormonal
therapy or chemotherapy completed at least six months prior to study
entry and not containing anthracyclines, adequate haematological,
renal, hepatic and cardiac function, measurable or evaluable disease.
A written informed consent was obtained.
Patients received a maximum of four cycles of the combination of E
and D. Four additional cycles of D as a single agent at the same dose
level were administered to responding patients. Response was defined
according to the WHO criteria [10]. E and D were administered at
escalating doses starting from E 75 mg/m2 and D 75 mg/m2 to E 120
mg/m2 and D 85 mg/m2; E was administered as a 15-minute infusion
followed, after a one-hour interval, by D given as a 1-hour infusion.
Treatment was repeated every three weeks provided a complete haema-
tological recovery had occurred. A three-day prophylactic medication
with oral dexamethasone (8 mg) 13 hours, 7 hours and 1 hour before D
and then twice daily on days I and 2 was routinely given in combina-
tion with oral cimetidine (300 mg) once daily. No G-CSF support was
routinely recommended unless febrile neutropenia or grade 4 pro-
longed haematological toxicity was encountered.
In the phase II study, previous treatment with anthracyclines
was allowed, with doxorubicin or E not exceeding 240 mg/m2 and 430
mg/m2 in the adjuvant setting, respectively. The treatment procedures
were the same as in the phase 1 study except that E was delivered at the
dose of 90 mg/m2 and D at the dose of 75 mg/m2. Responding patients
could receive a maximum of eight cycles of the combination.
Results
From July 1996 to May 1998, 92 patients (median age
50 years) were accrued in 2 studies. Their characteristics
are summarised in Table 1.
Twenty-three patients in the phase I study (55%) and
twenty-seven (54%) in the phase II study had dominant
visceral disease , whereas twenty-eight (66%) and thirty-
three (66%) patients had at least two metastatic sites.
Oestrogen receptor status was negative in 14 (33%) and
14 (28%) patients, respectively.
Twenty-eight patients (30%) (95% confidence limits:
26%—35%) had CNS relapse: this was cerebral in twenty-
five patients, leptomeningeal in two (cytologically con-
firmed) and both in one (Table 1). Median age was 54
years (range 39-66). Oestrogen receptor status was
negative in 10 patients (38%), positive in 12 (43%) and
unknown in 6. Six patients had LABC only and eight
were metastatic at first diagnosis (3 had lung, 2 nodal, 2
bone and 1 liver disease). Median disease-free interval
Number of patients
Age (years)
Median
Range
Dominant disease site at study entry
Viscera (liver)
Locoregional
Bone
Soft tissue
ER status
Positive
Negative
Unknown
Adjuvant CT
Response to E and D
CNS progression only (%)
Median progression-free interval
(months)
Phase I
42
51.5
32-68
23(12)
8
7
4
18
14
10
29
25
4(16)
5
Phase II
50
46
22-66
27(18)
10
10
3
27
14
9
22
34
7(20)
5
CNS
relapse
28
54
39-66
17(6)
6
4
1
12
10
6
11
19
11 (39)
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for the remaining 14 patients (50%) was 28 months (range
13-204); 11 of them (73%) had received adjuvant chemo-
therapy (CMF in 10 patients and LMF in 1 patient).
Seventeen patients (61%) had visceral dominant disease
at baseline, eleven patients presenting with lung metas-
tases, five with liver metastases, and one with both
disease sites.
Of the 28 patients with CNS relapse, 1 patient was
treated at the lowest dose level (E 75/D 75 mg/m2), 1 at
E 120/D 75 mg/m2 and 2 patients at the highest dose
level (E 120/D 85 mg/m2) in the phase I study, the
remaining 24 patients were treated at the recommended
dose level of E 90/D 75 mg/m2.
Nineteen patients (68%) had an objective response,
three had a stable disease and six had disease progression.
Only 5 out of the 16 patients (31%) who received
either whole brain radiotherapy (15 patients) or intra-
thecal chemotherapy (1 patient) survived more than 6
months from diagnosis (range 6-22), whereas median
survival from brain involvement was only 3 months (range
1-22) in the whole group of patients. Among the 11
patients with CNS progression of disease only, seven
received radiotherapy, three did not and one was treated
with intrathecal chemotherapy. Median survival in this
group of patients was six months (range 1-22).
Median time to the development of CNS metastases
from start of chemotherapy was 15 months (range 5-42),
excluding the 6 patients presenting CNS progression
within 3 months from study entry. In four of these six
cases, CNS progression was associated with concomitant
progressive disease in all metastatic sites of prior bulky
disease. All 28 patients presented with symptoms of intra-
cranial hypertension requiring further assessment (CT
scan and/or MRI). It is worth noting that 11 patients
(39%) had CNS progression only, without evidence of
new distant metastases.
We retrospectively assessed c-erbB-2 expression on
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histological specimens by immunohistochemistry (Dako
test): 16 cases were studied and 14 (87%) were positive
(10 cases were 3+, 1 was 2+ and 3 cases 1+), 1 was
negative and 1 was not evaluable.
Considering the overall group of patients who had
either a complete response or a partial response and who
subsequently experienced relapse, 11 out of 58 (19%) had
isolated CNS progression while maintaining a systemic
response.
Discussion
CNS relapse is not a common clinical finding during
treatment and follow-up of patients affected by breast
cancer. No clear-cut prognostic factors for the occurrence
of CNS metastases have been identified even if it is
common experience that brain relapse seems to develop
more frequently in younger patients with larger or aggres-
sive tumours (especially inflammatory breast cancer) [11].
The incidence of CNS involvement in our group of
patients appears to be higher than expected, especially
considering that the protocol was designed either as a
first-line treatment in the metastatic setting or as neo-
adjuvant treatment in patients with locally advanced
breast cancer only; moreover, the regimen was effective
and safe [8].
It is difficult to attribute our observation exclusively
to 'chance'. Almost half of the patients certainly had a
biologically aggressive disease as demonstrated by the
presence of two patients with inflammatory breast cancer,
oestrogen receptor negative tumours (38% of patients)
and by the presence of visceral disease at baseline (61%
of patients), but the median disease-free interval from
initial diagnosis and the overall CNS progression-free
interval were quite long (28 and 15 months, respectively).
In a similar poor prognosis population of metastatic
breast cancer patients only 3 out of 70 patients (14%)
had brain relapse as their only site of recurrence [12].
There are at least two other reports in the literature
suggesting that breast cancer patients treated with adju-
vant chemotherapy have an increased incidence of brain
metastases as the first site of recurrence, in comparison
with control patients who did not receive any kind of
treatment [13, 14]. This observation could easily be ex-
plained with the sanctuary site 'hypothesis', as a conse-
quence of an intact blood-brain barrier. On the other
hand, experimental studies in mice have shown that the
blood-brain barrier is intact inside and around brain
metastases smaller than 0.2 mm2 but not in larger
lesions, thus implying that the barrier should not be a
major obstacle for chemotherapy of brain metastases
[15], at least in the advanced phase of the disease.
Patients treated with adjuvant chemotherapy have longer
systemic disease-free intervals than untreated patients,
eventually allowing for the uncontrolled growth of can-
cer cells already present in the CNS at diagnosis.
As there is emerging evidence in the literature that
brain metastases respond to systemic chemotherapy
[3, 4] including drugs not considered to penetrate the
blood-brain barrier, such as taxanes [16], our findings
become even more intriguing. In fact, most patients
(68%) responded to treatment, with a median time to
disease progression of 8.5 months, and 39% of patients
with CNS relapse did not show systemic progression.
Even if we consider CNS as a sanctuary site, there
appears to be quite a particular disease aggressiveness
in our series of patients, who otherwise obtained an
overall good response to therapy, which prompted us to
report the data of an active and safe regimen [8].
The observation of a particular outcome prompted us
to review c-erbB-2 expression as a possible negative
predictive and prognostic marker. The information was
obtained in 16 patients and over-expression was retro-
spectively demonstrated in 14 patients (87%). However,
it is difficult to establish whether c-erbB-2 over-expres-
sion was associated with CNS involvement, because
no evaluation was carried out in patients without CNS
metastases due to the multi-institutional accrual of pa-
tients.
Freilich et al. [17] reported the CNS progression rate
in a series of 152 consecutive patients treated with
paclitaxel in 5 phase II trials at MSKCC. Seventy-eight
patients (51%) treated in the different protocols obtained
a partial (53 patients) or minor response (25 patients);
fifty-two of them had subsequent disease progression and
six of these (12%) had isolated CNS involvement while
maintaining a systemic response. As in our experience,
all patients developed neurologic symptoms that yielded
a neurologic and diagnostic assessment.
Several hypotheses could explain why patients with
untreated metastatic breast cancer who presumably no
longer have an intact blood-brain barrier and who
usually respond to systemic chemotherapy had such a
peculiar disease behaviour: possible local pharmacolog-
ical interactions between anthracyclines and taxanes
or detrimental effects of prophylactic corticosteroids
are worth considering. While it is well established that
patients undergoing chronic steroid therapy for organ
transplantation are at increased risk of developing tu-
mours, and in particular human herpes virus associated
Kaposi's sarcoma [18], no historical data on breast
cancer incidence are available so far.
Our study focuses on two important clinical issues:
first, it is extremely important to carefully evaluate the
development of any neurologic symptom in patients
treated with taxanes in order to differentiate between a
drug-induced peripheral neuropathy, which can cause
distal sensory or motor symptoms, and a true CNS
recurrence. Secondly, our observations raise the provo-
cative issue of prophylactic cerebral treatment, at least
in patients achieving a systemic complete remission that
can often translate into a long-lasting disease-free sur-
vival. Although this attitude does not represent standard
practice, it should be investigated in a clinical trial. This
is particularly important if we consider the dire short-
term prognosis in our group of patients after CNS
progression (3 months overall median survival).
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Further data are warranted and urgently needed to
better investigate this particular aspect of an otherwise
powerful drug combination widely used both in the
metastatic and in the adjuvant setting, especially in
high-risk patients who are also at higher risk of CNS
micrometastatic involvement. Another question relates
to breast cancer natural history: are we going to face,
in the near future, more patients with isolated brain
involvement as a consequence of prolonged survival
induced by adjuvant chemotherapy? If so, should we
plan new therapies and follow-up attitudes? If our data
with E and D, as well as those of MSKCC with anthra-
cyclines and paclitaxel [17] are confirmed by other groups,
a thorough investigation by pharmacologists will be of
great interest.
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